MCAS
MCID: MST020
MIFTS: 24

Mast Cell Activation Syndrome (MCAS)

Categories: Rare diseases

Aliases & Classifications for Mast Cell Activation Syndrome

MalaCards integrated aliases for Mast Cell Activation Syndrome:

Name: Mast Cell Activation Syndrome 53
Mcas 53

Classifications:



Summaries for Mast Cell Activation Syndrome

NIH Rare Diseases : 53 Mast cell activation syndrome (MCAS), is an immunological condition in which mast cells mistakenly release too many chemical mediators, resulting in several chronic symptoms involving the skin, gastrointestinal tract, heart, respiratory, and neurologic systems. Mast cells are present throughout most of our bodies and secrete different chemicals during allergic reactions. Symptoms include episodes of abdominal pain, cramping, diarrhea, flushing, itching, wheezing, coughing, lightheadedness and potential problems with "brain fog" or other difficulties with memory. The cause of MCAS is unknown. Treatment includes several combinations of medications like anti-histamines and mast cell stabilizers.

MalaCards based summary : Mast Cell Activation Syndrome, also known as mcas, is related to monoclonal mast cell activation syndrome and nguyen syndrome. An important gene associated with Mast Cell Activation Syndrome is CHIT1 (Chitinase 1). The drugs Protein Kinase Inhibitors and Imatinib Mesylate have been mentioned in the context of this disorder. Affiliated tissues include skin, heart and brain.

Wikipedia : 76 Mast cell activation syndrome (MCAS) is one type of mast cell activation disorder (MCAD), and is an... more...

Related Diseases for Mast Cell Activation Syndrome

Diseases related to Mast Cell Activation Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Related Disease Score Top Affiliating Genes
1 monoclonal mast cell activation syndrome 12.6
2 nguyen syndrome 11.5
3 richieri-costa/guion-almeida syndrome 11.2
4 gapo syndrome 11.1
5 benjamin syndrome 11.1
6 kagami-ogata syndrome 11.1
7 moyamoya disease 1 10.2
8 microcephaly 10.2
9 ischemia 10.0
10 carotid artery occlusion 10.0
11 fryns syndrome 10.0
12 dysostosis 10.0
13 cleft palate, isolated 9.9
14 cataract 9.9
15 cerebral hemorrhage 9.9
16 scoliosis 9.9
17 microphthalmia 9.9
18 hypospadias 9.9
19 intracranial aneurysm 9.9
20 pica disease 9.9
21 epilepsy 9.9
22 breast disease 9.9
23 brain edema 9.9
24 cerebrovascular disease 9.9
25 renal dysplasia 9.9
26 breast cancer 9.8
27 interstitial cystitis 9.8
28 angioedema 9.8
29 cystitis 9.8
30 food allergy 9.8
31 mastocytosis 9.8
32 pneumonia 9.8
33 mediastinitis 9.8
34 polycythemia 9.8
35 sickle cell disease 9.8
36 colchicine resistance 9.7
37 frontonasal dysplasia 1 9.7
38 spondyloepiphyseal dysplasia with congenital joint dislocations 9.7
39 hypertelorism 9.7
40 ovarian cancer 9.7
41 mccune-albright syndrome 9.7
42 rheumatoid arthritis 9.7
43 chromosome 2q35 duplication syndrome 9.7
44 tracheoesophageal fistula with or without esophageal atresia 9.7
45 down syndrome 9.7
46 abetalipoproteinemia 9.7
47 costello syndrome 9.7
48 gombo syndrome 9.7
49 hallermann-streiff syndrome 9.7
50 filippi syndrome 9.7

Graphical network of the top 20 diseases related to Mast Cell Activation Syndrome:



Diseases related to Mast Cell Activation Syndrome

Symptoms & Phenotypes for Mast Cell Activation Syndrome

Drugs & Therapeutics for Mast Cell Activation Syndrome

Drugs for Mast Cell Activation Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Protein Kinase Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
2 Imatinib Mesylate Phase 4,Phase 1,Phase 2,Not Applicable 220127-57-1 123596
3
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
4
Omalizumab Approved, Investigational Phase 2, Phase 3 242138-07-4
5
Denosumab Approved Phase 3 615258-40-7
6 Immunologic Factors Phase 2, Phase 3,Phase 1,Not Applicable
7 2-chloro-3'-deoxyadenosine Phase 2, Phase 3
8 Immunosuppressive Agents Phase 2, Phase 3,Phase 1,Not Applicable
9 Respiratory System Agents Phase 2, Phase 3
10 Anti-Asthmatic Agents Phase 2, Phase 3
11 Anti-Allergic Agents Phase 2, Phase 3
12 Bone Density Conservation Agents Phase 3
13 Pharmaceutical Solutions Phase 3,Phase 2
14
Midostaurin Approved, Investigational Phase 2 120685-11-2 104937 9829523
15
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
16
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Not Applicable 22916-47-8 4189
17
Everolimus Approved Phase 2 159351-69-6 6442177
18
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
19
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
20
Fludarabine Approved Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
21
Denileukin diftitox Approved, Investigational Phase 2 173146-27-5
22
Sunitinib Approved, Investigational Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102
23
Iron Approved Phase 2 7439-89-6 23925
24
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
25
Promethazine Approved, Investigational Phase 2 60-87-7 4927
26
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
27
Lenograstim Approved, Investigational Phase 2 135968-09-1
28
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
29
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
30
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
31
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
32
Granisetron Approved, Investigational Phase 2 109889-09-0 3510
33 tannic acid Approved Phase 2
34
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
35
Mycophenolic acid Approved Phase 2,Phase 1,Not Applicable 24280-93-1 446541
36
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
37
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
38
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
39
rituximab Approved Phase 2 174722-31-7 10201696
40
Acetaminophen Approved Phase 2 103-90-2 1983
41
alemtuzumab Approved, Investigational Phase 2 216503-57-0
42
Vidarabine Approved, Investigational Phase 2,Phase 1,Not Applicable 24356-66-9 32326 21704
43
Secretin Approved Phase 1, Phase 2 108153-74-8
44
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
45
Busulfan Approved, Investigational Phase 2 55-98-1 2478
46
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
47
Racepinephrine Approved Phase 2 329-65-7 838
48 Staurosporine Experimental Phase 2 62996-74-1
49
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
50 Specific substance maruyama Phase 2

Interventional clinical trials:

(show top 50) (show all 80)
# Name Status NCT ID Phase Drugs
1 Imatinib in KIT-negative Systemic Mastocytosis Completed NCT01297777 Phase 4 Imatinib Mesylate
2 Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis Unknown status NCT01602939 Phase 2, Phase 3 Cladribine and pegylated interpheron alpha-2a
3 The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients Completed NCT01333293 Phase 2, Phase 3 injections
4 Study on Mastocytosis for Rupatadine Treatment Completed NCT01481909 Phase 2, Phase 3 Rupatadin
5 Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Completed NCT00814073 Phase 3 Masitinib;Placebo
6 Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis Recruiting NCT03401060 Phase 3 Denosumab;Placebo
7 Midostaurin in Indolent Systemic Mastocytosis Unknown status NCT01920204 Phase 2 Midostaurin,
8 Evaluation of Response of Dasatinib to Treat Mastocytosis Unknown status NCT00979160 Phase 2 Dasatinib
9 Treatment of Indolent Systemic Mastocytosis With PA101 Completed NCT02478957 Phase 2 PA101;Placebo
10 Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation Completed NCT01266369 Phase 2 masitinib
11 Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis Completed NCT00449748 Phase 2 RAD001 (Everolimus)
12 Efficacy and Safety of TF002 in Cutaneous Mastocytosis Completed NCT00457288 Phase 2 TF 002
13 Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis Completed NCT00831974 Phase 2 masitinib (AB1010);masitinib (AB1010)
14 Stem Cell Transplantation to Treat Systemic Mastocytosis Completed NCT00006413 Phase 2
15 Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Completed NCT00493129 Phase 2 Ontak (Denileukin Diftitox)
16 Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis Completed NCT00769587 Phase 2 thalidomide
17 Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Completed NCT01807598 Phase 2 brentuximab vedotin
18 Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia Completed NCT00233454 Phase 2 Midostaurin
19 Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia Completed NCT00782067 Phase 2 Midostaurin (PKC412)
20 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
21 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed NCT00255346 Phase 2 Dasatinib (BMS-354825)
22 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers Completed NCT00109707 Phase 1, Phase 2 Nilotinib
23 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Completed NCT00171912 Phase 2 imatinib mesylate
24 Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis Completed NCT00555581 Phase 2 Imatinib Mesylate
25 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
26 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
27 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
28 Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD Completed NCT00186628 Phase 2 Rituximab;Anti-thymoglobulin, rabbit (ATG, rabbit ATG);Cyclosporine;Mycophenylate mofetil;Filgrastim;Granisetron;Solumedrol;Acetaminophen;Diphenhydramine;Hydrocortisone
29 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
30 Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis Recruiting NCT03770273 Phase 2
31 (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis Recruiting NCT03580655 Phase 2 Avapritinib
32 (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent and Smoldering Systemic Mastocytosis Recruiting NCT03731260 Phase 2 Avapritinib;Placebo
33 SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia) Recruiting NCT02268253 Phase 1, Phase 2 SL-401
34 Effect of Secretin in Functional Dyspepsia and Healthy Subjects Recruiting NCT03617861 Phase 1, Phase 2 Human Secretin;Placebo
35 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
36 Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia Active, not recruiting NCT03686345 Phase 2 Midostaurin
37 A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis Active, not recruiting NCT00890162 Phase 2 Epinephrine;Omalizumab (Xolair)
38 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
39 CD16/IL-15/CD33 Tri-Specific Killer Engagers (TriKEs) for High Risk Heme Malignancies Not yet recruiting NCT03214666 Phase 1, Phase 2 161533 Trike Phase I;161533 Trike Phase II
40 Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Not yet recruiting NCT03739606 Phase 2
41 Cromoglicate in Mastocytosis Terminated NCT01701843 Phase 2 Cromoglicate;Placebo
42 Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Terminated NCT02415608 Phase 2 Ibrutinib
43 Obatoclax for Systemic Mastocytosis Terminated NCT00918931 Phase 2 Obatoclax Mesylate
44 Sunitinib in Treating Patients With Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2 sunitinib malate
45 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
46 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
47 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies Recruiting NCT02561988 Phase 1 Avapritinib
48 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Recruiting NCT02571036 Phase 1 DCC-2618
49 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 Active, not recruiting NCT02808793 Phase 1 AK002
50 Clonal Mast Cell Disorders in Exercise-Induced Anaphylaxis Unknown status NCT01326741

Search NIH Clinical Center for Mast Cell Activation Syndrome

Genetic Tests for Mast Cell Activation Syndrome

Anatomical Context for Mast Cell Activation Syndrome

MalaCards organs/tissues related to Mast Cell Activation Syndrome:

41
Skin, Heart, Brain, Bone, Testes, Liver, Bone Marrow

Publications for Mast Cell Activation Syndrome

Articles related to Mast Cell Activation Syndrome:

(show top 50) (show all 60)
# Title Authors Year
1
A case of neuropathic pain in monoclonal mast cell activation syndrome. ( 29481890 )
2018
2
Mast Cell Activation Syndrome: Importance of Consensus Criteria and Call for Research. ( 29928922 )
2018
3
White matter abnormalities are also repeatedly present in patients with systemic mast cell activation syndrome. ( 29743606 )
2018
4
Idiopathic Mast Cell Activation Syndrome With Associated Salicylate Intolerance. ( 29637062 )
2018
5
Management of a Parturient with Mast Cell Activation Syndrome: An Anesthesiologist's Experience. ( 29951321 )
2018
6
Generalized pruritus relieved by NSAIDs in the setting of mast cell activation syndrome. ( 29577987 )
2018
7
Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence. ( 30007464 )
2018
8
Mast cell activation syndrome: High frequency of skin manifestations and anaphylactic shock. ( 30097253 )
2018
9
sRNA-dependent control of curli biosynthesis in Escherichia coli: McaS directs endonucleolytic cleavage of csgD mRNA. ( 29905843 )
2018
10
Characterization of Mast Cell Activation Syndrome. ( 28262205 )
2017
11
Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report. ( 28438191 )
2017
12
Successful Management of a Patient With Possible Mast Cell Activation Syndrome Undergoing Pulmonary Embolectomy: A Case Report. ( 28181942 )
2017
13
Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA. ( 29225779 )
2017
14
Mast Cell Activation Syndrome Mimicking Breast Cancer: Case Report With Pathophysiologic Considerations. ( 29305308 )
2017
15
Lower prevalence of vitamin D insufficiency in German patients with systemic mast cell activation syndrome compared with the general population. ( 29212100 )
2017
16
Successful targeted treatment of mast cell activation syndrome with tofacitinib. ( 28382662 )
2017
17
Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing. ( 28386644 )
2017
18
Mast Cell Activation Syndrome. ( 29282192 )
2017
19
Drug desensitization in 17-year-old male with Mast Cell Activation Syndrome, pneumonia, and antibiotic hypersensitivities. ( 30263994 )
2017
20
Hfq and three Hfq-dependent small regulatory RNAs-MgrR, RyhB and McaS-coregulate the locus of enterocyte effacement in enteropathogenic Escherichia coli. ( 27956465 )
2017
21
Investigating the physical stability of repackaged medicines stored into commercially available multicompartment compliance aids (MCAs). ( 28713440 )
2017
22
Possible mast cell activation syndrome in a patient undergoing long-term hemodialysis. ( 27033139 )
2016
23
Mast cell activation syndrome in pain syndromes bladder pain syndrome/interstitial cystitis and vulvodynia. ( 27297031 )
2016
24
Menstrual anaphylactoid reactions and presumed systemic mast cell activation syndrome. ( 27405897 )
2016
25
A novel combination of an IgE mediated adult onset food allergy and a suspected mast cell activation syndrome presenting as anaphylaxis. ( 27660640 )
2016
26
Ribonucleoprotein particles of bacterial small non-coding RNA IsrA (IS61 or McaS) and its interaction with RNA polymerase core may link transcription to mRNA fate. ( 26609136 )
2016
27
FLAIR Hyperintense Vessel Sign of Both MCAs with Severe Heart Failure. ( 27648320 )
2016
28
Anti-Amoxicillin Immunoglobulin E, Histamine-2 Receptor Antagonist Therapy and Mast Cell Activation Syndrome Are Risk Factors for Amoxicillin Anaphylaxis. ( 25968421 )
2015
29
Ketotifen use in a patient with fire ant hypersensitivity and mast cell activation syndrome. ( 25868710 )
2015
30
Mast Cell Activation Syndrome. ( 25944644 )
2015
31
Successful treatment of mast cell activation syndrome with sunitinib. ( 26072665 )
2015
32
Mast cell activation syndrome. ( 26816856 )
2015
33
Energy-dependent gas-phase fragmentation of fluorofullerene multiply charged anions (MCAs). ( 26272592 )
2015
34
Familial hypertryptasemia with associated mast cell activation syndrome. ( 25086867 )
2014
35
Mast cell activation syndrome as a significant comorbidity in sickle cell disease. ( 25171546 )
2014
36
Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11I^-prostaglandin2I+. ( 25439370 )
2014
37
Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome. ( 24950847 )
2014
38
Improved metastatic uterine papillary serous cancer outcome with treatment of mast cell activation syndrome. ( 24701700 )
2014
39
Utility of hydroxyurea in mast cell activation syndrome. ( 24192267 )
2013
40
Mast cell activation syndrome: a review. ( 23179866 )
2013
41
Immunology and clinical manifestations of non-clonal mast cell activation syndrome. ( 23212667 )
2013
42
Clonal mast cell activation syndrome with anaphylaxis to sulfites. ( 23816954 )
2013
43
Management of a parturient with mast cell activation syndrome. ( 23218498 )
2013
44
Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. ( 24565720 )
2013
45
Nonhistaminergic idiopathic angioedema may be a presentation of mast cell activation syndrome. ( 23967766 )
2013
46
Dual function of the McaS small RNA in controlling biofilm formation. ( 23666921 )
2013
47
Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. ( 22541416 )
2012
48
Sclerosing mediastinitis and mast cell activation syndrome. ( 22296862 )
2012
49
Mast cell activation syndrome (MCAS) diagnosed using double-balloon enteroscopy. ( 22396288 )
2012
50
Mast cell activation syndrome masquerading as agranulocytosis. ( 22338992 )
2012

Variations for Mast Cell Activation Syndrome

Expression for Mast Cell Activation Syndrome

Search GEO for disease gene expression data for Mast Cell Activation Syndrome.

Pathways for Mast Cell Activation Syndrome

GO Terms for Mast Cell Activation Syndrome

Cellular components related to Mast Cell Activation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 8.62 CHIT1 KIT

Sources for Mast Cell Activation Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....